Emyria Limited
Research Emyria Limited (EMD.AX) on Bullrun: market cap AUD 32.27M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEMD.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyAUD
- Market capAUD 32.27M
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 32.27M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.01 | n/a | n/a | n/a |
| FY2024 | AUD 2.20M | -AUD 11.46M | -AUD 5.52M | -7.6% | -0.03 | AUD 1.57M | AUD 1.72M | AUD 2.43M |
| FY2023 | AUD 1.59M | -AUD 5.13M | -AUD 6.99M | -40.7% | -0.02 | AUD 2.73M | AUD 1.27M | AUD 6.79M |
| FY2022 | AUD 1.35M | -AUD 7.33M | -AUD 7.46M | -73.6% | -0.03 | AUD 3.88M | AUD 632.70K | AUD 6.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 32.27M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Emyria Limited
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Emyria Limited's market cap?
Emyria Limited's market capitalization is AUD 32.27M.
What does Emyria Limited do?
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name.